Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
551-03-007 / 551-03-007 ISMRM Abstract

Longitudinal MRI Assessment of Lecanemab in Alzheimer’s Disease: Structural and CSF-Glymphatic Pathway Remodeling

Primary: Neuro - Alzheimer's Disease
Secondary: Neuro - Neurotherapeutics
551-03-007 · Advanced MRI Biomarkers of Brain Aging, Vascular Health, and Alzheimer’s Disease · Wednesday, 13 May, 4:00 PM–5:36 PM · Power Pitch Theatre 1
551-03-007 · Advanced MRI Biomarkers of Brain Aging, Vascular Health, and Alzheimer’s Disease · Wednesday, 13 May, 4:00 PM–5:36 PM · Power Pitch Theatre 1
Keywords: Treatment Alzheimer's Disease Choroid plexus Perivascular spaces (PVS)
Accepted
Yuxin Li1, Tao Gong 2, Jiaxiang xin3,4,5,6,7,8, guangbin wang1
1Department of Radiograpy, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, China
2Departments of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250022, China
3MR Collaborations, Siemens Healthineers Ltd., Shanghai, China
4Magnetic Resonance Research Collaboration, Siemens Healthineers Ltd, Shanghai, China
5Magnetic Resonance Research Collaboration, Shanghai, China
6MR Research Collaboration Team, Shanghai, China
7MR Research Collaboration, Siemens Healthineers Ltd., Beijing, China
8MR Research Collaboration, Siemens Healthineers Ltd., Shanghai, China
Presenting Author: Tao Gong

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. C. R. Jack et al., “NIA‐AA Research Framework: Toward a biological definition of Alzheimer’s disease,” Alzheimers Dement., vol. 14, no. 4, pp. 535–562, Apr. 2018, doi: 10.1016/j.jalz.2018.02.018. [doi]
2. L. Söderberg et al., “Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease,” Neurotherapeutics, vol. 20, no. 1, pp. 195–206, Jan. 2023, doi: 10.1007/s13311-022-01308-6. [doi]
3. C. H. Van Dyck et al., “Lecanemab in Early Alzheimer’s Disease,” N. Engl. J. Med., vol. 388, no. 1, pp. 9–21, Jan. 2023, doi: 10.1056/NEJMoa2212948. [doi]
4. H. Benveniste, X. Liu, S. Koundal, S. Sanggaard, H. Lee, and J. Wardlaw, “The Glymphatic System and Waste Clearance with Brain Aging: A Review,” Gerontology, vol. 65, no. 2, pp. 106–119, 2019, doi: 10.1159/000490349. [doi]
5. S. Lin et al., “Association of MRI Indexes of the Perivascular Space Network and Cognitive Impairment in Patients with Obstructive Sleep Apnea,” Radiology, vol. 311, no. 3, p. e232274, June 2024, doi: 10.1148/radiol.232274. [doi]
6. K. Alves De Lima, J. Rustenhoven, and J. Kipnis, “Meningeal Immunity and Its Function in Maintenance of the Central Nervous System in Health and Disease,” Annu. Rev. Immunol., vol. 38, no. 1, pp. 597–620, Apr. 2020, doi: 10.1146/annurev-immunol-102319-103410. [doi]
7. H. J. Drews et al., “Intranasal Losartan Decreases Perivascular Beta Amyloid, Inflammation, and the Decline of Neurogenesis in Hypertensive Rats,” Neurotherapeutics, vol. 16, no. 3, pp. 725–740, July 2019, doi: 10.1007/s13311-019-00723-6. [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/551-03-007